Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD

Prescription Drug User Fee Act (PDUFA) goal date of July 29, 2026 Prescription Drug User Fee Act (PDUFA) goal date of July 29, 2026

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.